PubRank

Josep Redon

Author PubWeight™ 173.73‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007 20.09
2 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013 12.73
3 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007 9.43
4 European Society of Hypertension recommendations for conventional, ambulatory and home blood pressure measurement. J Hypertens 2003 5.94
5 Increase in nocturnal blood pressure and progression to microalbuminuria in type 1 diabetes. N Engl J Med 2002 5.72
6 Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009 4.87
7 European Society of Hypertension position paper on ambulatory blood pressure monitoring. J Hypertens 2013 4.28
8 Prevalence and factors associated with circadian blood pressure patterns in hypertensive patients. Hypertension 2009 3.93
9 European Society of Hypertension guidelines for blood pressure monitoring at home: a summary report of the Second International Consensus Conference on Home Blood Pressure Monitoring. J Hypertens 2008 3.32
10 Practice guidelines of the European Society of Hypertension for clinic, ambulatory and self blood pressure measurement. J Hypertens 2005 3.15
11 Management of high blood pressure in children and adolescents: recommendations of the European Society of Hypertension. J Hypertens 2009 3.13
12 Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study. J Hypertens 2009 2.68
13 2013 ESH/ESC Practice Guidelines for the Management of Arterial Hypertension. Blood Press 2013 2.62
14 Added impact of obesity and insulin resistance in nocturnal blood pressure elevation in children and adolescents. Hypertension 2008 2.31
15 ESH position paper: renal denervation - an interventional therapy of resistant hypertension. J Hypertens 2012 2.24
16 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2016 2.09
17 Ambulatory blood pressure values in the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET). Hypertension 2012 2.02
18 Carotid-femoral pulse wave velocity assessment by two different methods: implications for risk assessment. J Hypertens 2015 1.98
19 Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Blood Press 2009 1.98
20 Antihypertensive activity of angiotensin II AT1 receptor antagonists: a systematic review of studies with 24 h ambulatory blood pressure monitoring. J Hypertens 2007 1.86
21 Blood pressure targets recommended by guidelines and incidence of cardiovascular and renal events in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET). Circulation 2011 1.77
22 Microvascular brain damage with aging and hypertension: pathophysiological consideration and clinical implications. J Hypertens 2011 1.76
23 Blood pressure and obesity exert independent influences on pulse wave velocity in youth. Hypertension 2012 1.70
24 Influence of concurrent obesity and low birth weight on blood pressure phenotype in youth. Hypertension 2009 1.64
25 Prevalence, persistence, and clinical significance of masked hypertension in youth. Hypertension 2005 1.61
26 European Society of Hypertension practice guidelines for ambulatory blood pressure monitoring. J Hypertens 2014 1.58
27 Associations of birth weight and postnatal weight gain with cardiometabolic risk parameters at 5 years of age. Hypertension 2014 1.52
28 Association of central and peripheral pulse pressure with intermediate cardiovascular phenotypes. J Hypertens 2012 1.49
29 2016 European Guidelines on cardiovascular disease prevention in clinical practice. Rev Esp Cardiol (Engl Ed) 2016 1.42
30 Regression of left ventricular hypertrophy and microalbuminuria changes during antihypertensive treatment. J Hypertens 2013 1.39
31 [Renal function as a prognostic marker of mortality in heart failure]. Med Clin (Barc) 2009 1.38
32 Blood pressure in chronic kidney disease stage 5D-report from a Kidney Disease: Improving Global Outcomes controversies conference. Kidney Int 2009 1.16
33 Blood pressure and LDL-cholesterol targets for prevention of recurrent strokes and cognitive decline in the hypertensive patient: design of the European Society of Hypertension-Chinese Hypertension League Stroke in Hypertension Optimal Treatment randomized trial. J Hypertens 2014 1.03
34 Prevalence and clinical characteristics of patients with true resistant hypertension in central and Eastern Europe: data from the BP-CARE study. J Hypertens 2013 0.94
35 The impact of the degree of obesity on the discrepancies between office and ambulatory blood pressure values in youth. J Hypertens 2006 0.93
36 Hypertension and atrial fibrillation: diagnostic approach, prevention and treatment. Position paper of the Working Group 'Hypertension Arrhythmias and Thrombosis' of the European Society of Hypertension. J Hypertens 2012 0.93
37 What the interventionalist should know about renal denervation in hypertensive patients: a position paper by the ESH WG on the interventional treatment of hypertension. EuroIntervention 2014 0.92
38 Common variants of the liver fatty acid binding protein gene influence the risk of type 2 diabetes and insulin resistance in Spanish population. PLoS One 2012 0.92
39 European Society of Hypertension Working Group on Obesity Obesity-induced hypertension and target organ damage: current knowledge and future directions. J Hypertens 2009 0.91
40 [ESH/ESC 2007 Guidelines for the management of arterial hypertension]. Rev Esp Cardiol 2007 0.90
41 Inadequate cytoplasmic antioxidant enzymes response contributes to the oxidative stress in human hypertension. Am J Hypertens 2007 0.88
42 Xanthine oxidoreductase polymorphisms: influence in blood pressure and oxidative stress levels. Pharmacogenet Genomics 2007 0.86
43 Renin polymorphisms and haplotypes are associated with blood pressure levels and hypertension risk in postmenopausal women. J Hypertens 2008 0.86
44 Determinants of urinary albumin excretion reduction in essential hypertension: A long-term follow-up study. J Hypertens 2006 0.85
45 Blood pressure and low-density lipoprotein-cholesterol lowering for prevention of strokes and cognitive decline: a review of available trial evidence. J Hypertens 2014 0.85
46 Association of a mineralocorticoid receptor gene polymorphism with hypertension in a Spanish population. Am J Hypertens 2009 0.84
47 New developments in the pathogenesis of obesity-induced hypertension. J Hypertens 2015 0.84
48 Agreement within Europe about antihypertensive treatment and education - results from the European Society of Hypertension questionnaire. J Hypertens 2010 0.84
49 2016 European Society of Hypertension guidelines for the management of high blood pressure in children and adolescents. J Hypertens 2016 0.83
50 Updated ESH position paper on interventional therapy of resistant hypertension. EuroIntervention 2013 0.83
51 Continuation of the ESH-CHL-SHOT trial after publication of the SPRINT: rationale for further study on blood pressure targets of antihypertensive treatment after stroke. J Hypertens 2016 0.83
52 Nocturnal blood pressure versus nondipping pattern: what do they mean? Hypertension 2007 0.83
53 Are physicians underestimating the challenges of hypertension management? Results from the Supporting Hypertension Awareness and Research Europe-wide (SHARE) survey. Eur J Prev Cardiol 2012 0.83
54 Rationale and methods of the cardiometabolic Valencian study (Escarval-Risk) for validation of risk scales in Mediterranean patients with hypertension, diabetes or dyslipidemia. BMC Public Health 2010 0.82
55 Polymorphisms of the UCP2 gene are associated with body fat distribution and risk of abdominal obesity in Spanish population. Eur J Clin Invest 2011 0.82
56 Measurement of microalbuminuria--what the nephrologist should know. Nephrol Dial Transplant 2005 0.81
57 Long-term impact of systolic blood pressure and glycemia on the development of microalbuminuria in essential hypertension. Hypertension 2005 0.81
58 The impact of birth weight on pulse pressure during adolescence. Blood Press Monit 2004 0.81
59 Dietary polyunsaturated fatty acids may increase plasma LDL-cholesterol and plasma cholesterol concentrations in carriers of an ABCG1 gene single nucleotide polymorphism: study in two Spanish populations. Atherosclerosis 2011 0.80
60 Prevalence and factors related to urinary albumin excretion in obese youths. J Hypertens 2013 0.79
61 Diagnosis and treatment of hypertension in children. Curr Hypertens Rep 2010 0.79
62 The effects of telmisartan alone or with hydrochlorothiazide on morning and 24-h ambulatory BP control: results from a practice-based study (SURGE 2). Hypertens Res 2012 0.79
63 Genetic bases of urinary albumin excretion and related traits in hypertension. J Hypertens 2010 0.79
64 [Practice guidelines 2007 for the treatment of arterial hypertension]. G Ital Cardiol (Rome) 2007 0.79
65 European Society of Hypertension Working Group on Obesity: background, aims and perspectives. J Hypertens 2007 0.79
66 Treatment of hypertension and the price to pay; adverse events and discontinuation from randomized treatment in clinical trials. J Hypertens 2016 0.78
67 Predictors of progression in hypertensive renal disease in children. J Clin Hypertens (Greenwich) 2004 0.78
68 Different impacts of cardiovascular risk factors on oxidative stress. Int J Mol Sci 2011 0.78
69 Increased oxidative stress levels and normal antioxidant enzyme activity in circulating mononuclear cells from patients of familial hypercholesterolemia. Metabolism 2009 0.78
70 [Differences between office and ambulatory control of hypertension in very elderly patients. The CARDIORISC - MAPAPRES project]. Med Clin (Barc) 2009 0.78
71 Urinary albumin excretion: lowering the threshold of risk in hypertension. Hypertension 2005 0.77
72 Sexual dimorphism in the transition from masked to sustained hypertension in healthy youths. Hypertension 2013 0.77
73 Impaired exercise tolerance is associated with increased urine albumin excretion in the early stages of essential hypertension. Eur J Prev Cardiol 2011 0.77
74 Reproducibility and validity of ambulatory blood pressure monitoring in children. Am J Hypertens 2002 0.77
75 Microalbuminuria in essential hypertension: redefining the threshold. J Hypertens 2002 0.77
76 Nocturnal hypertension: will control of nighttime blood pressure prevent progression of diabetic renal disease? Curr Hypertens Rep 2004 0.77
77 Association of selected ABC gene family single nucleotide polymorphisms with postprandial lipoproteins: results from the population-based Hortega study. Atherosclerosis 2010 0.77
78 Methodology and technology for peripheral and central blood pressure and blood pressure variability measurement: current status and future directions - Position statement of the European Society of Hypertension Working Group on blood pressure monitoring and cardiovascular variability. J Hypertens 2016 0.77
79 Gender differences related to the presence of atrial fibrillation in older hypertensive patients. World J Cardiol 2013 0.77
80 Morning and smooth 24-h ambulatory blood pressure control is not achieved in general practice: results from the SURGE observational study. J Hypertens 2013 0.76
81 Discordant response of glutathione and thioredoxin systems in human hypertension? Antioxid Redox Signal 2007 0.76
82 Target blood pressure in elderly hypertensive patients and in patients with diabetes mellitus. J Hypertens 2014 0.76
83 Influence of obesity in central blood pressure. J Hypertens 2015 0.76
84 Discrepancies in office and ambulatory blood pressure in adolescents: help or hindrance? Pediatr Nephrol 2007 0.75
85 [Limitations of blood pressure measurement outside the arm]. Med Clin (Barc) 2005 0.75
86 Reply. J Hypertens 2015 0.75
87 Should we look for silent pulmonary embolism in patients with deep venous thrombosis? BMC Cardiovasc Disord 2014 0.75
88 Necessity of add-on therapy in the treatment of hypertension: a new marker of high cardiovascular risk? J Hypertens 2012 0.75
89 Microalbuminuria as an intermediate endpoint in essential hypertension: evidence is coming. J Hypertens 2004 0.75
90 New insights into urinary proteins as markers of cardiovascular risk in hypertension. J Hypertens 2006 0.75
91 Reply. J Hypertens 2017 0.75
92 Issues in the development of new combinations of blood pressure lowering drugs. J Hypertens 2010 0.75
93 [Origins of hypertension: birth weight, a new issue]. Med Clin (Barc) 2002 0.75
94 Executive summary of the joint position paper on renal denervation of the Cardiovascular and Interventional Radiological Society of Europe and the European Society of Hypertension. J Hypertens 2016 0.75
95 [Obesity and hypertension]. Med Clin (Barc) 2007 0.75
96 Reply. J Hypertens 2016 0.75
97 Microalbuminuria in type 1 diabetes mellitus. J Hypertens 2004 0.75
98 Noninvasive cardiovascular imaging for evaluating subclinical target organ damage in hypertensive patients: a consensus article from the European Association of Cardiovascular Imaging, the European Society of Cardiology Council on Hypertension and the European Society of Hypertension. J Hypertens 2017 0.75
99 Reply. J Hypertens 2017 0.75
100 European Society of Hypertension Working Group on Obesity: obesity drugs and cardiovascular outcomes. J Hypertens 2011 0.75
101 Circadian changes in blood pressure and their relationships to the development of microalbuminuria in type 1 diabetic patients. Curr Diab Rep 2002 0.75
102 Renal function and attributable risk of death and cardiovascular hospitalization in patients with cardiovascular risk factors from a registry-based cohort: the Estudio Cardiovascular Valencia-risk study. J Hypertens 2016 0.75
103 Do genes modify the association of selenium and lipid levels? Antioxid Redox Signal 2015 0.75
104 [2016 European Guidelines on cardiovascular disease prevention in clinical practice]. Kardiol Pol 2016 0.75
105 Microalbuminuria in Type-1 diabetes mellitus. Blood Press 2003 0.75
106 Central blood pressure and pulse wave amplification across the spectrum of peripheral blood pressure in overweight and obese youth. J Hypertens 2016 0.75
107 Sympathetic neural activity, metabolic parameters and cardiorespiratory fitness in obese youths. J Hypertens 2016 0.75
108 Within-visit BP variability, cardiovascular risk factors, and BP control in central and eastern Europe: findings from the BP-CARE study. J Hypertens 2015 0.75
109 Expertise: no longer a sine qua non for guideline authors? J Hypertens 2017 0.75